---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-277662"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:37:58.725756+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# AN2 Therapeutics Q3 2025 net loss $9.4M, cash $65.1M; Chagas Phase 1 ongoing

## Summary
- Net loss of $9.4M vs $12.7M in Q3 2024, R&D expense $7.0M (down from $8.3M), G&A $3.0M.
- Cash, equivalents and investments $65.1M at Sept 30, 2025; projected runway into 2028.
- Chagas Phase 1 of oral AN2-502998 advancing; data expected Q1 2026, Phase 2 start in 2026.
- M. abscessus program: IIT expected to begin enrollment early 2026, pending regulatory clearance.
- Collaboration with GSK on boron-based TB drugs, with third-year Gates Foundation funding.

## SEC filing metadata
- accession: 0001193125-25-277662
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000119312525277662/0001193125-25-277662-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000119312525277662/antx-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-277662
- JSON: https://secwatch.observer/filing/0001193125-25-277662.json
- Plain text: https://secwatch.observer/filing/0001193125-25-277662.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.